Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19: Lessons for Future Pandemics.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40011416.
- Also identified by DOI 10.1007/s11606-025-09386-w and PMC identifier 12325127.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We conducted a single-center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021, and May 14, 2021. Among the 2406 eligible participants, mAb treatment was significantly underutilized among African American patients compared to White patients (OR 1.8; 95% CI 1.5-2.1). The higher proportion of refusals and cancellations of mAb treatment may suggest a higher level of hesitancy among African American patients (OR 1.7; 95% CI 1.3-2.1). Evaluating the reasons and addressing racial disparities in hesitancy of novel therapeutics under Emergency Use Authorization (EUA) offer a critical opportunity to address the inequities in pandemic care.
Medical subject headings
- Antibodies, Monoclonal
- COVID-19
- COVID-19 Drug Treatment
- Healthcare Disparities
- Patient Acceptance of Health Care